Abstract:To discover novel BChE inhibitors, a hierarchical virtual screening protocol followed by biochemical evaluation was applied. The most potent compound 8012-9656 (eqBChE IC50 = 0.18 ± 0.03 μM, hBChE IC50 = 0.32 ± 0.07 μM) was purchased and synthesized. It inhibited BChE in a noncompetitive manner and could occupy the binding pocket forming diverse interactions with the target. 8012-9656 was proven to be safe in vivo and in vitro and showed comparable performance in ameliorating the scopolamine-induced cognition impairment to tacrine. Additionally, treatment with 8012-9656 could almost entirely recover the Aβ1–42 (icv)-impaired cognitive function to the normal level and showed better behavioral performance than donepezil. The evaluation of the Aβ1–42 total amount confirmed its anti-amyloidogenic profile. Moreover, 8012-9656 possessed blood–brain barrier (BBB) penetrating ability, a long T1/2, and low intrinsic clearance. Hence, the novel potential BChE inhibitor 8012-9656 can be considered as a promising lead compound for further investigation of anti-AD agents.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01129?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01129</a>.Basic information and target inhibitory activities of the 13 hit compounds; binding mode with hBChE and alignment of binding mode with donepezil in hAChE of 8012–9656; structural spectrum data of intermediates, final compounds (8012–9656) and tacrine; molecular formula strings of all compounds; everyday body weight of mice in the acute toxicity assay; standard curve of the mouse Aβ1–42 ELISA kit (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01129/suppl_file/jm0c01129_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Non-rigid range-scan alignment using thin-plate splines

Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B

Verbs and nouns from a cross-linguistic perspective

Relinquishing the reins.

[Synthesis and AchE Inhibitory Activity of 2-Phenoxy-indan-1-one Derivatives].

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Synthesis and biological evaluation of novel flavonoid derivatives as dual binding acetylcholinesterase inhibitors.

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine

Design, synthesis and anti-Alzheimer's disease activity evaluation of C-3 arylated huperzine A derivatives

Design, synthesis and biological evaluation of new carbazole-coumarin hybrids as dual binding site inhibitors of acetylcholinesterase

Characteristics of Huperzine A Structure in Huperzine A -Acetylcholinesterase Complex-A Quantum Chemistry Study

Evaluation of the in Vitro and in Vivo Metabolic Pathway and Cytochrome P450 Inhibition/induction Profile of Huperzine A.

Huperzine A from Huperzia serrata: a review of its sources, chemistry, pharmacology and toxicology

Design, Synthesis and Bioactivity Evaluation of Coumarin–BMT Hybrids as New Acetylcholinesterase Inhibitors

Design, Synthesis and Evaluation of Flavonoid Derivatives As Potent AChE Inhibitors.

Synthesis, Biological Evaluation, and In Silico Studies of New Acetylcholinesterase Inhibitors Based on Quinoxaline Scaffold

New 2-Aryl-9-methyl-β-carbolinium salts as Potential Acetylcholinesterase Inhibitor agents: Synthesis, Bioactivity and Structure–Activity Relationship

Searching for the Multi-Target-Directed Ligands Against Alzheimer'S Disease: Discovery of Quinoxaline-Based Hybrid Compounds with Ache, H3r and Bace 1 Inhibitory Activities

Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities.

Immunohistochemical expression of TGF-β1 and MMP-9 in periapical lesions.

Discovery and Biological Evaluation of a Novel Highly Potent Selective Butyrylcholinsterase Inhibitor